48155bad-7de9-401d-a495-972cbbb8f276
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- GLYCOLYSIS+0.300
- MTORC1_SIGNALING+0.300
- PANCREAS_BETA_CELLS+0.300
- ANDROGEN_RESPONSE+0.200
- ANGIOGENESIS+0.200
- CHOLESTEROL_HOMEOSTASIS+0.200
- HYPOXIA+0.200
- PROTEIN_SECRETION+0.200
- SPERMATOGENESIS+0.200
- ADIPOGENESIS+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.500
- ALLOGRAFT_REJECTION-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- IL6_JAK_STAT3_SIGNALING-0.300
- INFLAMMATORY_RESPONSE-0.300
- DNA_REPAIR-0.200
- G2M_CHECKPOINT-0.200
- MYC_TARGETS_V1-0.200
- P53_PATHWAY-0.200
- TNFA_SIGNALING_VIA_NFKB-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518427 | — | E | 0.768 |
| 2 | TCGA-AN-A0FV-01A-11R-A00Z-07 | — | C | 0.763 |
| 3 | 737bc806-018c-401d-b3ef-ffd3c896c01c | — | — | 0.732 |
| 4 | SRR8518414 | — | C | 0.715 |
| 5 | 034df4c4-52bd-4025-aee4-ad630d0d00af | — | — | 0.714 |
| 6 | TCGA-BH-A1EV-01A-11R-A137-07 | — | C | 0.708 |
| 7 | SRR8518184 | — | F | 0.698 |
| 8 | 3cf35e3b-812f-4cc1-bd37-e78fd6af6dc4 | — | — | 0.695 |
| 9 | MNG527 | — | — | 0.691 |
| 10 | TCGA-2F-A9KQ-01A-11R-A38B-07 | — | — | 0.691 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |